Conditions: Pulmonary Arterial Hypertension
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7
Healthy volunteers: no

Brief summary:
This clinical trial will study the safety, tolerability, and pharmacodynamics of single doses of MK-8892 in participants with pulmonary arterial hypertension (PAH). The primary objective is to estimate the measured peak effect of the highest acutely tolerated (HAT) single oral dose of MK-8892 on pulmonary vascular resistance (PVR).

Detailed description:

Arms:
arm 1: Participants will receive a single oral dose of 1 mg MK-8892. arm 2: Participants will receive a single oral dose of 4 mg MK-8892. arm 3: Participants will receive a single oral dose of 8 mg MK-8892.

Interventions: intervention 1: MK-8892
Intervention descriptions: intervention 1: Single oral capsule with 1 mg, 4 mg, or 8 mg of MK-8892

Protocol document: